载双药含钾的石墨烯氧化物纳米载体用于鸡尾酒式药物递送治疗人乳腺癌。
Dual Drug Loaded Potassium-contained Graphene Oxide as a Nanocarrier in Cocktailed Drug Delivery for the Treatment of Human Breast Cancer.
机构信息
Department of Chemistry, Prof. Rajendra Singh Nanoscience and Nanotechnology Centre, D.S.B. Campus, Kumaun University, Nainital, Uttarakhand, India.
University of Petroleum and Energy Studies (UPES), School of Engineering, Energy Acres, Bidholi, Dehradun 248007, Uttarakhand, India.
出版信息
Curr Drug Deliv. 2023;20(7):943-950. doi: 10.2174/1567201819666220524152558.
BACKGROUND
The combinatorial use of anticancer drugs, dual or multiple, with a specific nanocarrier is one of the most promising attempts in drug delivery. The current work reports potassium contained graphene oxide (K-GO) as a nanocarrier in the drug delivery system of two anticancer drugs, gefitinib (GEF) and camptothecin (CPT), simultaneously.
METHODS
To characterize K-GO, K-GO-related single and combined drug systems, different techniques have been performed and studied using the following spectroscopic tools, such as Thermo Gravimetric Analysis (TGA 4000), UV-visible spectroscopy, Raman spectroscopy, and Transmission electron microscopy (TEM). The in vitro cytotoxicity tests of K-GO, single drug system, and the combined drug system were also performed in the human breast cancer MDA-MB-231 cells.
RESULTS
The release profile of the dual drug conjugates grafted onto the surface of K-GO was found to be up to 38% in PBS solution over 72 hours. The percentage of MDA-MB-231 cell viability was about 18% when treated with K-GO-GEF-CPT combined system; for K-GO, K-GO-GEF, and K-GO-CPT, the cell viability was 79%, 31%, and 32%, respectively.
CONCLUSION
We studied the loading, release, and delivery of two anticancer drugs onto the fluorescent nanocarrier. Features, such as superb aqueous solubility, excellent biocompatibility, richness in potassium, and fluorescent nature, which can monitor the delivery of drugs, make them a promising nanocarrier for single or multiple drug delivery. Furthermore, our novel findings revealed that the loading capacity and cytotoxicity of the combined drug-loaded system are superior to the capacity of the individual drug system for human breast cancer cells.
背景
将抗癌药物与特定的纳米载体组合使用，双药或多药联合，是药物传递中最有前途的尝试之一。目前的工作报道了含钾氧化石墨烯（K-GO）作为纳米载体，同时在吉非替尼（GEF）和喜树碱（CPT）两种抗癌药物的药物传递系统中。
方法
为了对 K-GO 进行表征，使用以下光谱工具对 K-GO 及其相关的单药和联合药物系统进行了不同的技术研究，如热重分析（TGA 4000）、紫外-可见光谱、拉曼光谱和透射电子显微镜（TEM）。还在人乳腺癌 MDA-MB-231 细胞中进行了 K-GO、单药系统和联合药物系统的体外细胞毒性试验。
结果
发现接枝在 K-GO 表面的双药偶联物在 PBS 溶液中 72 小时内的释放率高达 38%。当用 K-GO-GEF-CPT 联合系统处理时，MDA-MB-231 细胞的存活率约为 18%；对于 K-GO、K-GO-GEF 和 K-GO-CPT，细胞存活率分别为 79%、31%和 32%。
结论
我们研究了两种抗癌药物在荧光纳米载体上的负载、释放和传递。其具有极好的水溶性、优异的生物相容性、丰富的钾含量和荧光性质，可以监测药物的传递，使它们成为单药或多药传递的有前途的纳米载体。此外，我们的新发现表明，载药联合系统的载药量和细胞毒性优于人乳腺癌细胞中单个药物系统的载药量。
Zotero 插件